Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 6:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 116 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Conduction Disorder of the Heart Clear all
Recruiting No phase listed Observational

Targeted Ablation to Isolate Scar Channels Causing Ventricular Tachycardia

NCT07814079
View directory record Official record
Conditions
Ventricular Tachycardia (VT), Ischemic Cardiomyopathy, Nonischemic Cardiomyopathy
Interventions
Selective Substrate Isolation
Procedure
Lead sponsor
New York Medical College
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 17, 2026, 6:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects

NCT00316459
View directory record Official record
Conditions
Healthy, Long QT Syndrome
Interventions
ERB-041
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 12, 2007 · Synced Sep 17, 2026, 6:37 PM EDT
Withdrawn Not applicable Interventional

Anti-arrhythmic Medication v. MRI-Merge Ablation in the Treatment of Ventricular Tachycardia

NCT00721032
View directory record Official record
Conditions
Ventricular Tachycardia
Interventions
MRI guided VT ablation, Increased dose of amiodarone
Procedure · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Sep 17, 2026, 6:37 PM EDT
Completed Phase 4 Interventional Results available

Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)

NCT03346057
View directory record Official record
Conditions
Reversal of Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Sugammadex 16 mg/kg, Neostigmine + Glycopyrrolate, Rocuronium, Vecuronium
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
20
States / cities
Birmingham, Alabama • Tucson, Arizona • Loma Linda, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Sep 17, 2026, 6:37 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).

NCT03464019
View directory record Official record
Conditions
Paroxysmal Supraventricular Tachycardia
Interventions
Etripamil, Placebo, Etripamil Test Dose
Drug
Lead sponsor
Milestone Pharmaceuticals Inc.
Other
Eligibility
18 Years and older
Enrollment
1,097 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
54
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Cerritos, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 17, 2026, 6:37 PM EDT
Withdrawn No phase listed Observational

Use of a Novel Contact Force Sensing Catheter for AF Ablation - Impact of TactiCath on Dormant Conduction Across the Pulmonary Veins

NCT02666729
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
AF Ablation with contact force information, AF Ablation without contact force information
Procedure
Lead sponsor
Dhanunjaya Lakkireddy, MD, FACC
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2016 · Synced Sep 17, 2026, 6:37 PM EDT
Terminated Phase 1 Interventional

High Sodium Diet and External Abdominal Compression in POTS

NCT01771484
View directory record Official record
Conditions
Postural Orthostatic Tachycardia Syndrome
Interventions
External automated abdominal binder
Device
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 60 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 17, 2026, 6:37 PM EDT
Completed Not applicable Interventional Results available

Using Non-Fluoroscopic Imaging Devices to Decrease Radiation Exposure During Ablation of Supraventricular Tachycardia

NCT00979303
View directory record Official record
Conditions
Supraventricular Tachycardia
Interventions
Intracardiac echocardiography and 3D navigational system
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 21 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Sep 17, 2026, 6:37 PM EDT
Completed Not applicable Interventional

AIMIGo 12L ECG Synthesis Software Pivotal Study for Arrythmia Detection

NCT06123130
View directory record Official record
Conditions
Arrhythmias, Cardiac, Atrial Fibrillation, Atrial Flutter, Bradycardia, Tachycardia
Interventions
Vectorcardiography (VECG)
Device
Lead sponsor
HeartBeam, Inc.
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
5
States / cities
Atlanta, Georgia • Tucker, Georgia • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced Sep 17, 2026, 6:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers

NCT01353729
View directory record Official record
Conditions
Influenza, Human
Interventions
600 mg zanamivir + moxifloxacin placebo, 1200 mg zanamivir + moxifloxacin placebo, zanamivir placebo + moxifloxacin placebo, zanamivir placebo + 400 mg moxifloxacin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 17, 2026, 6:37 PM EDT
Withdrawn No phase listed Observational

The Ability Of The PD2i Cardiac Analyzer To Predict Risk Of Ventricular Tachyarrhythmic Events

NCT00510731
View directory record Official record
Conditions
Tachycardia, Ventricular, Cardiac Sudden Death
Interventions
Not listed
Lead sponsor
Vicor Technologies, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
19
States / cities
Los Angeles, California • San Ramon, California • Walnut Creek, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Sep 17, 2026, 6:37 PM EDT
Completed Phase 4 Interventional

Reduce Ventricular Pacing in Dual Chamber Implantable Cardioverter Defibrillators Using AutoIntrinsic Conduction Search Study

NCT00187239
View directory record Official record
Conditions
Arrhythmia
Interventions
Autointrinsic Conduction Search Algorithm
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Pomona, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 3, 2019 · Synced Sep 17, 2026, 6:37 PM EDT
Recruiting Not applicable Interventional

Randomized Assessment of TcMS for VT Storm

NCT05599022
View directory record Official record
Conditions
Ventricular Tachycardia
Interventions
Magnetic Stimulation
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 17, 2026, 6:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function

NCT02441829
View directory record Official record
Conditions
Long QT Syndrome
Interventions
Eleclazine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
5
States / cities
DeLand, Florida • Miami, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Sep 17, 2026, 6:37 PM EDT
Terminated Phase 2 Interventional Results available

Treatment of Ventricular Tachyarrhythmias Refractory To Shock With Beta Blockers: The SHOCK and BLOCK Trial

NCT00401882
View directory record Official record
Conditions
Cardiac Arrest, Sudden Cardiac Death, Ventricular Fibrillation, Tachycardia, Ventricular
Interventions
Epinephrine, Metoprolol
Drug
Lead sponsor
David Haines, MD
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Sep 17, 2026, 6:37 PM EDT
Completed Not applicable Interventional

FLExAbility Sensor Enabled Substrate Targeted Ablation for the Reduction of VT Study

NCT03490201
View directory record Official record
Conditions
Ventricular Tachycardia
Interventions
Market Approved RF Ablation System, FlexAbility SE Ablation Catheter
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
592 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Sep 17, 2026, 6:37 PM EDT
Completed No phase listed Observational

Electrocardiographic Diagnostic Performance of the Apple Watch Augmented With an Artificial Intelligence Algorithm

NCT05167058
View directory record Official record
Conditions
Atrial Fibrillation, Tachycardia, Bradycardia, Premature Supraventricular Beat, Premature Ventricular Contraction
Interventions
Cardiologs Platform
Device
Lead sponsor
Cardiologs Technologies
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Hackensack, New Jersey • Ridgewood, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Sep 17, 2026, 6:37 PM EDT
Completed Phase 1 Interventional

Analysis of Adenosine on Sinus and Atrioventricular Nodal Conduction in the Pediatric Transplanted Heart

NCT02462941
View directory record Official record
Conditions
Sinus Bradycardia, Atrioventricular Block
Interventions
Adenosine, Cardiac catheterization
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
6 Months to 25 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Sep 17, 2026, 6:37 PM EDT
Terminated No phase listed Observational

All Inclusive Kodex - EPD Study

NCT05489445
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
KODEX - EPD
Device
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Sep 17, 2026, 6:37 PM EDT
Completed Phase 1 Interventional

Study of the Effect of GS-6615 in Subjects With LQT-3

NCT01849003
View directory record Official record
Conditions
Long QT Syndrome
Interventions
GS-6615
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 16, 2014 · Synced Sep 17, 2026, 6:37 PM EDT
Recruiting Phase 4 Interventional

Adenosine vs Diltiazem for Treatment of SVT in the ED

NCT06993038
View directory record Official record
Conditions
Supraventricular Tachycardia (SVT)
Interventions
adenosine, diltiazem
Drug
Lead sponsor
Anne E. Zepeski
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 17, 2026, 6:37 PM EDT
Withdrawn Not applicable Interventional

TcMS to Treat Ventricular Tachycardia

NCT05016921
View directory record Official record
Conditions
Ventricular Tachycardia
Interventions
TcMS
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Sep 17, 2026, 6:37 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

QTc Study of Rosi XR in Healthy Volunteers

NCT00884533
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rosi XR, Placebo, Moxifloxacin
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Sep 17, 2026, 6:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate How VI-0521 Affect Cardiac Repolarization in Healthy Male and Female Volunteers

NCT00839891
View directory record Official record
Conditions
Torsades de Pointes
Interventions
VI-0521
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
19 Years to 50 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 20, 2010 · Synced Sep 17, 2026, 6:37 PM EDT